There are two fundamental strategies to block, manage, and control the progression of the hormone-dependent types of BC: (1) blocking the ER pathway using antagonists or degraders or (2) inhibiting estrogen production using aromatase inhibitors (AIs) [17,18,19,20,21,22]. Here, ESR1 is linked to breast cancer.